-
-
Call more information
660-596-2224 -
Authors: Susan Curling, M.D., M.B.A. ASA Monitor 10 2015, Vol.79, 18-19. Susan Curling, M.D., M.B.A., is former Medical Director for Quality, Memorial Hermann Hospital Northeast, Humble, Texas. The core goal of leadership is to develop an inspired culture that changes a job into a calling. Several physician anesthesiologists have been instrumental in accomplishing this goal. In a […]
Read MoreAuthors: Nicholas M. Halzack, M.P.H. et al ASA Monitor 10 2015, Vol.79, 10-12. The relationship between surgical volume and patient outcomes has been studied extensively since the 1980s. The “volume” variable is often measured in two ways: hospital volume (the amount of surgeries the hospital performs) and surgeon volume (the amount of surgeries each surgeon performs). So, […]
Read MoreThe US Food and Drug Administration (FDA) has granted accelerated approval to Praxbind (idarucizumab, Boehringer Ingelheim) to rapidly reverse the blood-thinning effects of the anticoagulant Pradaxa (dabigatran, Boehringer Ingelheim). “The anticoagulant effects of Pradaxa are important and life-saving for some patients, but there are situations where reversal of the drug’s effects is medically necessary,” said […]
Read MoreA perspective in the New England Journal of Medicine discusses the FDA’s risk assessment of serious neurologic events associated with the off-label use of epidural glucocorticoid injections. In April 2014, the FDA required a label change for injectable corticosteroids — which are commonly used to treat neck and back pain — to warn about “rare but serious,” […]
Read MoreAuthors: Hassan Farhan, M.D. et al Anesthesiology 10 2015. Abstract Muscle weakness is common in the surgical intensive care unit (ICU). Low muscle mass at ICU admission is a significant predictor of adverse outcomes. The consequences of ICU-acquired muscle weakness depend on the underlying mechanism. Temporary drug-induced weakness when properly managed may not affect outcome. Severe […]
Read More